

Food and Drug Administration Advisory Committee Member Acknowledgment of Financial Interests

Name of Advisory Committee Member: Evan Bloch, M.D., M.S.

Committee: Blood Products Advisory Committee (BPAC)

Meeting Date: May 9, 2024

I acknowledge that contingent upon public disclosure of the following financial interest(s) related to the agenda item: Discussions of general strategies to reduce the risk of transfusion-transmitted malaria by testing blood donations from donors at risk of malaria exposure, I may be considered for participation in the advisory committee meeting described above.

Type of Interest	Nature	Magnitude	
II. Other Imputed Interests			
NIH grant to his employer Johns Hopkins.	Study involves a product from an affected firm.	\$750,000 - \$1,000,000	

Type of Interest	Nature	Magnitude	
II. Other Imputed Interests			
DOD contract to his employer Johns Hopkins.	Study involves a product from an affected firm.	\$5,000,000 -\$7,500,000	

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

---S--

Signature

4/19/2024

Date

U.S. Food & Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 www.fda.gov